Over 80% of all diseases are caused by genetic mutations. These diseases cause over 44M deaths a year.
Gene therapies could offer a cure and save millions of people. However, over 99% of clinical trials fail, mostly due to problems with a single key component: the in-vivo delivery system.
We are creating an ML-powered bio-platform to solve targeted delivery and make gene therapies much more likely to succeed. We have already shown promising pre-clinical results.
Our advisors include a Director of the Gene Center Munich, the Science Chair at the International Society for Extracellular Vesicles, and an ex-GP at Speedinvest.
